

Certificate of Analysis for NR-46062

Staphylococcus aureus, Strain H2138 (Isolate 10)

Catalog No. NR-46062

Product Description: Staphylococcus aureus (S. aureus), strain H2138 (Isolate 10) was isolated in 2002 from a wound drain site of 52-year-old male in the United Kingdom. S. aureus, strain H2138 (Isolate 10) is a linezolid-resistant S. aureus (LRSA), methicillin-resistant S. aureus (MRSA) strain. It was deposited as being resistant to linezolid, tedizolid, ciprofloxacin, oxacillin and penicillin and having an intermediate resistance to erythromycin. S. aureus, strain H2138 (Isolate 10) is the second clinically isolated linezolid-resistant MRSA strain.

Lot¹: 62401823 Manufacturing Date: 27FEB2014

TEST	SPECIFICATIONS	RESULTS
Phenotypic Analysis		
Cellular morphology	Gram-positive cocci	Gram-positive cocci
Colony morphology ²	Report results	Circular, low convex, entire, smooth
· · · · · · · · · · · · · · · · ·		and gray (Figure 1)
Motility (wet mount)	Report results	Non-motile
Hemolysis ²	Report results	β-hemolytic
Biochemical characterization		
Catalase	Positive	Positive
Coagulase ³	Report results	Positive
VITEK [®] 2 Compact (GP card)	≥ 90% probability of being S. aureus	S. aureus (99% probability) ⁴
VITEK [®] MS (MALDI-TOF)	Consistent with S. aureus	S. aureus (99.9%)
Antibiotic Susceptibility Profile		
VITEK [®] (AST-GP71 card) ⁵		
Beta-lactamase ⁶	Report results	Positive
Cefoxitin screen	Report results	Positive
Benzylpenicillin	Report results	Resistant (≥ 0.5 µg/mL)
Oxacillin	Resistant	Resistant (≥ 4 µg/mL)
Gentamicin	Sensitive	Sensitive (≤ 0.5 μg/mL)
Ciprofloxacin	Resistant	Resistant (≥ 8 µg/mL)
Levofloxacin	Report results	Resistant (≥ 8 µg/mL)
Moxifloxacin	Report results	Resistant (≥ 8 µg/mL)
Clindamycin (inducible resistance)	Report results	Negative
Clindamycin `	Sensitive	Sensitive (≤ 0.25 μg/mL)
Quinupristin/dalfopristin	Sensitive	Sensitive (≤ 0.25 μg/mL)
Linezolid	Resistant	Resistant (≥ 8 µg/mL)
Daptomycin	Report results	Sensitive (= 0.5 µg/mL)
Vancomycin	Sensitive	Sensitive (≤ 0.5 µg/mL)
Minocycline	Report results	Sensitive (≤ 0.5 µg/mL)
Tetracycline	Report results	Sensitive (≤ 1 µg/mL)
Tigecycline	Report results	Sensitive (≤ 0.12 µg/mL) ⁷
Nitrofurantoin	Report results	Sensitive (≤ 16 μg/mL)
Rifampicin	Report results	Sensitive (≤ 0.5 µg/mL)
Trimethoprim/sulfamethoxazole	Sensitive	Sensitive (≤ 10 µg/mL)
Etest [®] antibiotic test strips ⁸		
Chloramphenicol ⁹	Report results	Sensitive (= 6 µg/mL)
Teicoplanin ⁹	Sensitive	Sensitive (= 1 µg/mL)
Erythromycin ⁹	Intermediate	Sensitive (= 0.39 µg/mL) ¹⁰
Genotypic Analysis		
Sequencing of 16S ribosomal RNA gene	≥ 99% sequence identity to <i>S. aureus</i>	100% sequence identity to S. aureus
(~ 1460 base pairs)	type strain (Genbank: L37597)	type strain (Genbank: L37597)

BEI Resources www.beiresources.org E-mail: contact@beiresources.org

Tel: 800-359-7370 Fax: 703-365-2898



Certificate of Analysis for NR-46062


SUPPORTING INFECTIOUS DISEASE RESEARCH

TEST	SPECIFICATIONS	RESULTS
Purity (post-freeze) ¹¹	Consistent with expected colony morphology	Consistent with expected colony morphology
Viability (post-freeze) ²	Growth	Growth

¹S. aureus, strain H2138 (Isolate 10) was deposited to BEI Resources as part of the NARSA collection. NR-46062 was produced by inoculation of the deposited material into Tryptic Soy broth and grown 27 hours at 37°C in an aerobic atmosphere. Broth inoculum was added to Tryptic Soy agar with 5% defibrinated sheep blood kolles which were grown 23 hours at 37°C in an aerobic atmosphere to produce this lot.

²20 hours at 37°C in an aerobic atmosphere on Tryptic Soy agar with 5% defibrinated sheep blood

Figure 1: Colony Morphology



Date: 28 MAR 2016

Signature:

BEI Resources Authentication

ATCC[®], on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC[®]'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

BEI Resources www.beiresources.org E-mail: contact@beiresources.org

Tel: 800-359-7370 Fax: 703-365-2898

³4 hours at 37°C in rabbit serum with 0.15% EDTA (Coagulase Plasma BBL™ 240827)

⁴Percent probabilities above 90% indicate a close match to the typical biochemical pattern for the given organism, with a percent probability of 99% being a perfect match between the test reaction pattern and the unique biochemical pattern of the given organism or organism group. For additional information, please refer to O'Hara, C.M. and J. M. Miller. "Evaluation of the Vitek 2 ID-GNB Assay for Identification of Members of the Family *Enterobacteriaceae* and Other Nonenteric Gram-Negative Bacilli and Comparison with the Vitek GNI+ Card." <u>J. Clin. Microbiol.</u> 41 (2003): 2096-2101. PubMed: 12734254.

⁵Minimum Inhibitory Concentration (MIC); MIC Interpretation Guideline: CLSI M100-S22 (2012)

⁶The production of beta-lactamase was detected using a Cefinase™ Paper Disc (BBL™ 231650).

⁷MIC Interpretation Guideline: EUCAST Version 4.0 (2014)

⁸24 hours at 37°C in an aerobic atmosphere on Mueller Hinton agar

⁹For both chloramphenicol (bioMérieux Etest[®] 412308) and teicoplanin (bioMérieux Etest[®] 412459), a MIC ≤ 8 μg/mL is sensitive, a MIC = 16 μg/mL is intermediate and a MIC ≥ 32 μg/mL is resistant. For erythromycin (bioMérieux Etest[®] 412333), a MIC ≤ 0.5 μg/mL is sensitive, a MIC between 1 and 4 μg/mL is intermediate and a MIC ≥ 8 μg/mL is resistant.

¹⁰S. aureus, strain H2138 (Isolate 10) was deposited as having an intermediate susceptibility to erythromycin. Antibiotic susceptibility testing performed in duplicate determined that strain H2138 (Isolate 10) is susceptible to erythromycin.

¹¹Purity of this lot was assessed for 7 days on Tryptic Soy agar with 5% defibrinated sheep blood at 37°C in an aerobic atmosphere.